Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial

Background: Recurrent herpes simplex labialis (HSL) occurs in 20% to 40% of the US population. Although the disease is self-limiting in persons with a healthy immune response, patients seek treatment because of the discomfort and visibility of a recurrent lesion. Objective: Our purpose was to determine whether docosanol 10% cream (docosa nol) is efficacious compared with placebo for the topical treatment of epis odes of acute HSL. Methods: Two identical double-blind, placebo-controlled studies were conduc ted at a total of 21 sites. Otherwise healthy adults, with documented histo ries of HSL, were randomized to receive either docosanol or polyethylene gl ycol placebo and initiated therapy in the prodrome or erythema stage of an episode. Treatment was administered 5 times daily until healing occurred (i e, the crust fell off spontaneously or there was no longer evidence of an a ctive lesion) with twice-daily visits. Results: The median time to healing in the 370 docosanol-treated patients w as 4.1 days, 18 hours shorter than observed in the 367 placebo-treated pati ents (P = .008; 95% confidence interval [CI]: 2, 22). The docosanol group a lso exhibited reduced times from treatment initiation to (1) cessation of p ain and all other symptoms (itching, burning, and/or tingling; P = .002; 95 % CI: 3, 16.5); (2) complete healing of classic lesions (P = .023; 95% CI: 1, 24.5); and (3) cessation of the ulcer or soft crust stage of classic les ions (P < .001; 95% CI: 8, 25). Aborted episodes were experienced by 40% of the docosanol recipients versus 34% of placebo recipients (P = .109; 95 CI for odds ratio: 0.95, 1.73). Adverse experiences with docosanol were mild and similar to those with placebo. Conclusion: Docosanol applied 5 times daily is safe and effective in the tr eatment of recurrent HSL. Differences in healing time compared favorably wi th those reported for the only treatment of HSL that has been approved by t he Food and Drug Administration.